- $36.58bn
- $37.04bn
- $4.69bn
- 95
- 18
- 91
- 76
Annual cashflow statement for Resmed, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 622 | 475 | 779 | 898 | 1,021 |
| Depreciation | |||||
| Non-Cash Items | 124 | 104 | 120 | 92.7 | 159 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -97.9 | 1.41 | -708 | -462 | 44.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | 802 | 737 | 351 | 693 | 1,401 |
| Capital Expenditures | -106 | -117 | -156 | -134 | -115 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -73.9 | -41.6 | -73.9 | -1,026 | -155 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -180 | -158 | -230 | -1,160 | -270 |
| Financing Cash Flow Items | -46.4 | -53.7 | -52.4 | -33 | -10.1 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -317 | -765 | -128 | 423 | -1,119 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 316 | -168 | -21.6 | -45.8 | 10.5 |